The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.
| Level | Code | Title | |
|---|---|---|---|
| 1 | R | Respiratory system | |
| 2 | R03 | Drugs for obstructive airway diseases | |
| 3 | R03B | Other drugs for obstructive airway diseases, inhalants | |
| 4 | R03BB | Anticholinergics | |
| 5 | R03BB05 |
The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. The DDD is a unit of measurement and does not necessarily reflect the recommended or Prescribed Daily Dose. Therapeutic doses for individual patients and patient groups will often differ from the DDD as they will be based on individual characteristics (such as age, weight, ethnic differences, type and severity of disease) and pharmacokinetic considerations.
| Route | Amount |
|---|---|
| RESPIR - Respiratory (Inhalation) (powder) | 644 mg |
| Active Ingredient | Description | |
|---|---|---|
| Aclidinium |
Aclidinium is a competitive, selective muscarinic receptor antagonist (also known as an anticholinergic), with a longer residence time at the M3 receptors than the M2 receptors. M3 receptors mediate contraction of airway smooth muscle. Inhaled aclidinium acts locally in the lungs to antagonise M3 receptors of airway smooth muscle and induce bronchodilation. |
| Title | Information Source | Document Type | |
|---|---|---|---|
| BRETARIS GENUAIR Inhalation powder | European Medicines Agency (EU) | MPI, EU: SmPC |
Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.
